Olaparib kills cancer cells by blocking the PARP protein, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more vulnerable to anticancer treatments. Olaparib is approved for treating some patients with ovarian cancer. It is taken orally (by mouth).
In this study, researchers want to identify the highest dose of olaparib that can be given safely in combination with other chemotherapy drugs in patients newly diagnosed with ovarian, fallopian tube, or primary peritoneal cancer. In addition to olaparib, patients will receive cisplatin (given intraperitoneally — into the abdomen through a port), paclitaxel (given intravenously or intraperitoneally), and bevacizumab (given intravenously).
Doctors also want to see if a patient’s BRCA mutation status affects the way they respond to treatment.